Comparative Pharmacology
Head-to-head clinical analysis: SEZABY versus TOVALT ODT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SEZABY versus TOVALT ODT.
SEZABY vs TOVALT ODT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Positive allosteric modulator of GABA-A receptors, enhancing inhibitory neurotransmission.
Tovalt ODT (selegiline) is a selective, irreversible inhibitor of monoamine oxidase type B (MAO-B). At therapeutic doses, it inhibits MAO-B more selectively than MAO-A, leading to increased levels of dopamine in the brain.
58 mg subcutaneously once monthly (every 30 days).
20 mg sublingually as needed for BTP, with a minimum interval of 2 hours between doses; maximum 4 doses per day.
None Documented
None Documented
The terminal elimination half-life of Sezaby is approximately 24 hours in healthy adults. This supports once-daily dosing. In patients with hepatic impairment, half-life may be prolonged.
Terminal elimination half-life approximately 40–60 hours after multiple dosing; clinical context: reaches steady-state after 2–3 weeks.
Sezaby undergoes extensive hepatic metabolism, with approximately 75% of the dose excreted in feces as metabolites and 20% in urine as unchanged drug and metabolites. Renal clearance accounts for less than 5% of total clearance.
Primarily hepatic metabolism; 70–80% as inactive metabolites in urine, <5% unchanged in urine, 20–30% fecal.
Category C
Category C
Atypical Antipsychotic
Atypical Antipsychotic